For that article we spoke with Albert Li, medical and surgical retina specialist and Clinical Assistant Professor of Ophthalmology at Zucker School of Medicine at Hofstra/Northwell, who had presented data at ARVO indicating that Ozempic was associated with higher rates of DR, as well as other adverse ocular events, when compared to other glucagon-like peptide 1 (GLP-1) receptor agonists, such as Tanzeum, Trulicity, and Victoza
It is also said that vision changes such as increased sensitivity to light, blurred vision, or even trouble telling blue and green colours apart might also occur
The Phase 2 data, while exceptional, is preliminary by regulatory standards
Limiting alcohol often leads to better, faster results, especially during early treatment stages
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study J Dermatolog Treat